Skip to content

Arpeggio Bio

YC S19 · Active · Arpeggio Bio develops drugs targeting transcription factors using AI…

Competitors

Adjacent

Also from S19 in AI

All of S19

About Arpeggio Bio

Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.

YC batch
S19 · Summer 2019
Status, per YC
Active
Category
AI
Team size
20
Location
Boulder, CO, USA
Checked
36m ago

YC tags: Biotech, Genomics, Drug discovery

Arpeggio Bio in S19: 176 companies, 26% AI

Arpeggio Bio: questions

Which YC batch was Arpeggio Bio in?

Arpeggio Bio was in Y Combinator's Summer 2019 batch (S19).

Is Arpeggio Bio still active?

Y Combinator lists Arpeggio Bio as active.

Where is Arpeggio Bio based?

Arpeggio Bio lists Boulder, CO, USA as its location on YC's directory.

Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.

New startups by email

Mondays: new YC data, AI and devtools companies and status changes, only when something changed.

Double opt-in. Unsubscribe any time.